CYP2C8

Cytochrome P450 enzyme that metabolises repaglinide, pioglitazone, paclitaxel and amodiaquine.

CYP2C8 inhibition (e.g. gemfibrozil + repaglinide) raises substrate concentrations and the risk of hypoglycaemia; induction reduces the effect.

The gemfibrozil + repaglinide interaction is clinically significant (severe hypoglycaemia) and documented in the repaglinide label.